In biopharma, the decisive questions often appear after the scientific concept has been validated.
Can the formulation be stabilised? Can the process be transferred? Can the product be filled aseptically at the right scale? Can release and stability testing support clinical and commercial supply? Can device integration be managed without adding late-stage risk?
The presence of ten23 health in Visp gives these questions a concrete industrial context in Valais.
With sites in Basel and Visp, ten23 health operates as a CDMO focused on injectable medicines. Its scope covers formulation and process development, sterile manufacturing, device assembly, analytical testing, quality control and regulatory support.
A fast-growing CDMO footprint
The company has grown quickly since its launch. According to its 2025 Fairstainability Report announcement, ten23 health reached 240 employees across three facilities by 31 December 2025.
Its Visp site is a central part of that expansion. The VIVA2 facility includes QC microbiology laboratories as well as Line 2 and Line 3 sterile production lines. Earlier expansion plans described the facility as a 5,000 m2 manufacturing site designed to add more than 30 million units per year of fill-and-finish capacity and create more than 100 jobs.
The technical profile matters. Line 2 is designed for sterile commercial supplies of ready-to-use syringes, cartridges and vials. Line 3 addresses liquid or freeze-dried clinical and commercial vial supplies.
For injectable medicines, this is not generic capacity. It sits close to the specific constraints of modern parenteral development: container compatibility, lyophilisation, aseptic process robustness, visual inspection, cold storage, microbiology and release testing.
Quality control as part of the value chain
A useful signal came in December 2025, when ten23 health announced that its Swissmedic-approved QC laboratories in Basel and Visp had received FDA approval in connection with a US customer’s commercial product.
The scope includes GMP-compliant analytical release testing and stability studies, including microbiology, content, purity, identity and pharmacopeial testing.
For companies developing injectable drug products, this is strategically relevant. It reduces the need to treat development, manufacturing and testing as separate workstreams. It also strengthens the case for integrated planning across clinical and commercial phases.
In practice, these are the steps where timelines, regulatory confidence and product readiness can be won or lost.
Why the Swiss context matters
The broader Swiss biotech environment also supports this reading.
The Swiss Biotech Report 2026 recorded CHF 7.5 billion in sector revenues for 2025, up from CHF 7.2 billion in 2024. Swiss biotech companies raised CHF 2.6 billion in funding, with privately funded companies reaching a record CHF 1.15 billion, up 38 percent from the previous year. R&D investment remained high at CHF 2.5 billion, while employment in Swiss R&D biotech companies reached more than 21,000 FTEs.
One detail is especially relevant here: the report links revenue growth partly to companies maturing towards the commercial stage and to growing demand for specialised CDMO services.
That places ten23 health in a wider industrial pattern. As more biotech assets move beyond early development, the need for specialised development, sterile manufacturing and release-testing capacity becomes more visible.
Valais as a manufacturing-intensive life sciences region
Valais is not the Swiss region with the highest concentration of headquarters or venture capital. Its relevance is different.
The canton is strongest where life sciences innovation meets industrial execution. Visp, in particular, has become associated with large-scale biopharmaceutical manufacturing, GMP operations and specialised production infrastructure.
ten23 health adds depth in sterile fill-finish and injectable drug products. This complements the broader regional manufacturing base and reinforces Valais as a place where biotech and biopharma companies can find operational capabilities, not only ecosystem visibility.
For companies assessing Switzerland, this distinction is important. The question is not whether an ecosystem sounds innovative. The question is whether it can support the technical, regulatory and industrial steps that make a product viable.
A useful signal for biopharma companies
The most interesting point about ten23 health in Visp is not its presence alone. It is the type of capability it brings into the regional value chain.
Injectable medicines require tight coordination between formulation, filling, device interface, quality control and regulatory expectations. Small decisions made early can affect manufacturability, stability, usability and supply readiness later.
That is why integrated CDMO capacity matters.
In Valais, ten23 health gives this part of the value chain a visible and current proof point: 240 employees across three facilities, expanded sterile production lines in Visp, FDA-approved QC labs, and a role in a Swiss biotech market where specialised CDMO demand is becoming more structurally important.
For a professional life sciences audience, that is the real signal. Valais is not only a place where life sciences companies are present. It is a region where parts of the biopharma execution chain are being built, expanded and regulated at international level.
Sources for figures: ten23 health 2025 Fairstainability Report announcement, ten23 health press releases, Swiss Biotech Report 2026, EY summary of the Swiss Biotech Report 2026.
